Pfizer and its German partner BioNTech will submit their emergency authorization request of their COVID-19 vaccine candidate to the FDA today.
If approved, they says doses could come as early as next month if approved.
The action comes days after the company announced that its vaccine appears 95% effective at preventing mild to severe COVID-19 disease in a large, ongoing study.